AstraZeneca (AZN) Receives a Sell From UBS
AstraZeneca Price Target Raised to $95.00/Share From $90.00 by TD Cowen
AstraZeneca Analyst Ratings
TD Cowen Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca: A Buy Rating Justified by Strong Growth Potential and Robust Pipeline
Deutsche Bank Reaffirms Their Hold Rating on AstraZeneca (AZN)
Kepler Capital Remains a Hold on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Hold From DZ BANK AG
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $89
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $136
AstraZeneca's Strong Q2 Performance and Positive Outlook Justify Buy Rating
Jefferies Remains a Hold on AstraZeneca (AZN)
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), AstraZeneca (AZN) and Icon (ICLR)
AstraZeneca: Strong Q2 Performance and Promising Pipeline Justify Buy Rating
UBS Sticks to Its Sell Rating for AstraZeneca (AZN)
AstraZeneca: Strong Growth and Resilience Justify Buy Rating
Deutsche Numis Reaffirms Their Hold Rating on AstraZeneca (AZN)
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca: Strong Sales Growth and Upward Guidance Potential Justify Buy Rating